ETX.L - e-Therapeutics plc

LSE - LSE Delayed Price. Currency in GBp
0.00 (0.00%)
As of 4:30PM BST. Market open.
Stock chart is not supported by your current browser
Previous Close7.25
Bid7.00 x 0
Ask7.50 x 0
Day's Range7.00 - 7.30
52 Week Range6.70 - 12.25
Avg. Volume17,962
Market Cap19.474M
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Press Releases
  • ACCESSWIRE3 months ago

    Edison Issues Update On e-Therapeutics (ETX)

    LONDON, UK / ACCESSWIRE / April 23, 2018 / With the refocusing of the business and the new CEO's strategic review now implemented, e-Therapeutics (LSE: ETX) finds itself with the NDD platform and at least ...

  • Business Wire4 months ago

    e-therapeutics plc: Full Year Results

    e-therapeutics plc , the drug discovery company, announces its full year results for the year ended 31 January 2018.

  • ACCESSWIRE6 months ago

    Edison Issues Update on e-Therapeutics (ETX)

    LONDON, UK / ACCESSWIRE / January 5. 2018 / e-Therapeutics' (LSE: ETX) Network-Driven Drug Discovery (NDD) platform has begun to deliver encouraging data that should support out-licensing of its immuno-oncology ...

  • Business Wirelast year

    e-Therapeutics Announces Outcome of Strategic Review and Future Plans

    e-Therapeutics plc : Upon the completion of Ray Barlow’s first three months as CEO of e-Therapeutics, the Company outlines below the conclusion of the strategic review for its investors and other stakeholders.